Protrainy Raises Seed Funding from IIMA Ventures and Prominent Indian & US Angels to Upskill India's Core Engineers
New Delhi [India], August 5: Protrainy, an ed-tech platform focused on upskilling core engineers across sectors like construction, manufacturing, oil & gas, renewables, ESG, and architecture, has raised an undisclosed amount in seed funding. The round was led by IIMA Ventures, with participation from leading Indian and US-based angel investors including Dhiraj Sinha (Co-Founder, SucSEED Indovation), Suresh Reddy,Dr.Moti Vyas, Avantika Sahay, AIC Nalanda, and others.
The fresh capital will be used to strengthen content development, boost marketing and user acquisition efforts, and grow the core team to meet rising demand for industry-relevant technical education.
Founded by Biswajit Shaw, an engineer with on-ground experience at JSW, Protrainy was born out of a firsthand understanding of the disconnect between traditional engineering education and industry expectations. Co-founder Bishal Shaw later joined the venture, helping shape it into a scalable, structured learning platform for India's next generation of core engineers.
"We started Protrainy to address a critical skill gap in professional education across core sectors like construction, manufacturing, and energy. This investment is not just capital, it's a vote of confidence in our mission to make Industry Ready® learning accessible to every engineering student and professional in India. It aligns strongly with the vision of Viksit Bharat 2047," said Biswajit Shaw, Founder & CEO of Protrainy.
Protrainy offers a mix of cohort-based learning, on-demand video courses, and project-driven modules, all led by seasoned industry professionals. The platform has already built strong traction, with over 20,000 learners having completed its programs and a growing community of more than 100,000 users across its ecosystem. Notably, more than 70% of its learners have gone on to secure new roles, salary increases, or promotions at leading firms.
Protrainy has partnered with top globally recognized institutions and departments like EICT Academy IIT Guwahati,I Hub Divya Sampark IIT Roorkee, AICTE NEAT 4.0 and other acclaimed institutions and seasoned technical professionals from leading corporations. Through these collaborations, Protrainy is launching vetted and co-branded upskilling programs designed to deliver Industry Ready® capabilities to both professionals and students.
"Protrainy is solving a niche but vital challenge with a scalable, impact-driven model. Its mission to improve employability among India's core engineers fits well with our investment philosophy. We're proud to back a founder who understands this industry from the inside out," said Vipul Patel, Partner - Seed Investing at IIMA Ventures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
24 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
Hans India
27 minutes ago
- Hans India
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.
Indian Express
27 minutes ago
- Indian Express
Now, Aadhaar mandatory to avail benefits of Delhi govt schemes
Now, having an Aadhar card is mandatory to avail the benefits of the schemes of the Delhi government. Lieutenant Governor VK Saxena has approved the BJP government's proposal to make the document mandatory for the issuance of income certificates in the Capital. The income certificate is a key document for availing financial benefits under a range of government schemes in the Capital. 'The move aims at eliminating any irregularity or malpractice in issuing income certificates to the applicants and thereby ensuring that only genuine beneficiaries registered under a scheme or financial assistance get the benefit,' a statement by the Raj Niwas underlined. The proposal, endorsed by Chief Minister Rekha Gupta, seeks to bring the service of issuing income certificates under Section 7 of the Aadhaar Act, 2016. This provision allows the state or Central government to make Aadhaar-based authentication compulsory for identifying individuals receiving subsidies, services, or benefits funded through the Consolidated Fund of India of the state. The income certificate issued by the Revenue department is used to determine eligibility for several welfare schemes, including tuition fee reimbursement for students from SC, ST, and OBC communities; pensions; and health-related financial assistance under the Delhi Arogya Kosh. Using Aadhaar would help simplify service delivery, improve transparency, and ensure that benefits reach only eligible individuals, officials in the Revenue Department said. It would also eliminate the need to submit multiple documents to establish identity. The Unique Identification Authority of India (UIDAI) on November 25, 2019, had authorised state governments to mandate Aadhaar authentication for schemes funded from the Consolidated Fund of the State. As per the notification, individuals not possessing an Aadhaar number currently but seeking benefits under the mentioned schemes will now be required to enrol for Aadhaar. In the case of minors, Aadhaar Enrolment ID or Biometric Update ID, along with a birth certificate or school ID bearing the parent's name and signed by the school principal, will be accepted. Adults without Aadhaar can furnish the enrolment slip along with a government-issued document such as a bank passbook, PAN card, passport, Kisan passbook, or driving licence. Saxena has asked the Revenue department to undertake a public awareness campaign to inform citizens about the Aadhaar requirement, so that genuine beneficiaries are not denied their entitlements.
